Proliferative Diabetic Retinopathy Market driven by rising disease prevalence
Proliferative Diabetic Retinopathy (PDR) describes the advanced stage of diabetic eye disease characterized by abnormal new blood vessel growth on the retina.
Leading therapeutic products include anti-VEGF injections, corticosteroid implants, and laser photocoagulation systems.
Anti-VEGF agents such as ranibizumab and aflibercept offer targeted inhibition of vascular endothelial growth factor, reducing neovascularization and lowering the risk of vision loss. Laser photocoagulation remains a cornerstone intervention, sealing off leaking vessels and stabilizing retinal tissue. Corticosteroid implants provide sustained anti-inflammatory effects, decreasing the frequency of intravitreal injections.
These treatment modalities offer clear advantages—improved visual acuity, reduced complications, and enhanced patient compliance—addressing an urgent need for effective management of Proliferative Diabetic Retinopathy Market.
The Proliferative Diabetic Retinopathy Market is estimated to be valued at USD 2.70 Bn in 2025 and is expected to reach USD 5.89 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.8% from 2025 to 2032.
‣ Proliferative Diabetic Retinopathy Market - https://www.coherentmi.com...
Proliferative Diabetic Retinopathy (PDR) describes the advanced stage of diabetic eye disease characterized by abnormal new blood vessel growth on the retina.
Leading therapeutic products include anti-VEGF injections, corticosteroid implants, and laser photocoagulation systems.
Anti-VEGF agents such as ranibizumab and aflibercept offer targeted inhibition of vascular endothelial growth factor, reducing neovascularization and lowering the risk of vision loss. Laser photocoagulation remains a cornerstone intervention, sealing off leaking vessels and stabilizing retinal tissue. Corticosteroid implants provide sustained anti-inflammatory effects, decreasing the frequency of intravitreal injections.
These treatment modalities offer clear advantages—improved visual acuity, reduced complications, and enhanced patient compliance—addressing an urgent need for effective management of Proliferative Diabetic Retinopathy Market.
The Proliferative Diabetic Retinopathy Market is estimated to be valued at USD 2.70 Bn in 2025 and is expected to reach USD 5.89 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.8% from 2025 to 2032.
‣ Proliferative Diabetic Retinopathy Market - https://www.coherentmi.com...
12:33 PM - Jun 23, 2025 (UTC)
